Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07586293Not Yet Recruiting

Histidine and Immunotherapy Response in Colorectal Cancer

Role: lead

NCT07519681Not ApplicableNot Yet Recruiting

Effects of Berberine on the Human Gut Microbiome

Role: lead

NCT07577505Not ApplicableNot Yet Recruiting

Histidine Supplementation for Antitumor Immunity in Colorectal Cancer

Role: lead

NCT06356597Phase 2Active Not Recruiting

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Role: lead

NCT04885426Not ApplicableUnknown

Metformin for the Prevention of CRA Recurrence

Role: lead

All 5 trials loaded